Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Mar 20, 2024 12:04pm
122 Views
Post# 35942956

RE:LEVEL 2 SHOWS Ver Few SELLERS

RE:LEVEL 2 SHOWS Ver Few SELLERS

I hear ya Rev 

The best I can do is nibble and grab very small amounts. 

Spring/Summer catalysts will make it even more difficult to acquire, such as:

- Enrolment updates - getting closer to the end goal 

- Baxter making final decisions concerning Vantive 

- Paradigm hasn't cut back on their revenue projections but they did improve their probability of success quesstimates and they now see faster enrolment - so I would expect them to start adjusting their SP targets higher ( when you discount cash flows a shorter timeframe improves the NPV) 

- more scuttlebut in the US hospitals about this Open Label Trial. 
 

Let's see. 


MM 

<< Previous
Bullboard Posts
Next >>